Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2016 / Cilt: 26 - Sayı: 2

A rare presentation of thyrotoxicosis: Gynecomastia

Tirotoksikozun ender bir başvuru nedeni: Jinekomasti

Pages
172–174
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report a 66-year-old male patient with bilateral gynecomastia was evaluated Alındığı tarih: 10.02.2016 and it has been emphasized that thyrotoxicosis should be considered in the differential diagnosis of gynecomastia even though thyrotoxicosis symptoms are not in the Kabul tarihi: 17.02.2016

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gynecomastia is the proliferation of the glandular breast tissue in men .
📊
Key Findings & Data:The main factor that led to the development of gynecomastia is deterioration of sex hormone balance due to increased production of estrogen or decreased levels of androgen.
💡
Conclusion & Impact:In this case report a 66-year-old male patient with bilateral gynecomastia was evaluated Alındığı tarih: 10.02.2016 and it has been emphasized that thyrotoxicosis should be considered in the differential diagnosis of gynecomastia even though thyrotoxicosis symptoms are not in the Kabul tarihi: 17.02.2016
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Gynecomastia is the proliferation of the glandular breast tissue in men . It is enlargement of breast. often with a benign course . The main factor that led to the development of gynecomastia is deterioration of sex hormone balance due to increased production of estrogen or decreased levels of androgen. Therefore, physiological causes, endocrine dysfunctions, systemic diseases and medications that may affect the sex hormone levels should be considered in the assessment of patients with gynecomastia. Although gynecomastia has been associated with thyrotoxicosis for a long time , quiet rarely the patients are presented with gynecomastia and limited to case reports. In this case report a 66-year-old male patient with bilateral gynecomastia was evaluated Alındığı tarih: 10.02.2016 and it has been emphasized that thyrotoxicosis should be considered in the differential diagnosis of gynecomastia even though thyrotoxicosis symptoms are not in the Kabul tarihi: 17.02.2016

Özet

Jinekomasti, erkeklerde memedeki glanduler yapının proliferasyonu sonucu oluşan ve sıklıkla benign klinik seyirli meme büyümesidir. Jinekomasti gelişimine neden olan ana faktör östrojen üretiminde artış veya androjen seviyesinde azalma ile seks hormon etkilerindeki balansın bozulmasıdır. Dolayısı ile jinekomastili hasta değerlendirmesinde fizyolojik nedenler, endokrin disfonksiyonlar, sistemik hastalıklar ve seks hormon düzeylerini etkileyebilecek ilaçlar göz önünde bulundurulmalıdır. Jinekomasti uzun zamandan beri tirotoksikozla ilişkilendirilmiş klinik bir durum olmasına rağmen, jinekomasti ile başvuran tirotoksikoz olgusu oldukça enderdir ve olgu sunumlarıyla sınırlıdır. Bu olgu sunumunda, bilateral jinekomasti ile başvuran 66 yaşında bir erkek hasta değerlendirilerek, tirotoksikoz semptomları ön planda olmasa bile jinekomasti ayırıcı tanısında tirotoksikozun göz önüne alınması gerektiği vurgulanmıştır. Bu durumun akılda tutulması hem altta yatan patolojinin hem de jinekomastinin tedavisi için önem taşımaktadır

🔖

Cite This Article

İLHAN, M., TURGUT, S. (2016). A rare presentation of thyrotoxicosis: Gynecomastia. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 26 - Sayı: 2, 172–174. https://ajindex.com/articles/205059

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Rahmani S, Turton P, Shaaban A, Dall B. Overview of gyne- comastia in the modern era and the Leeds Gynaecomastia Investigation algorithm. Breast J 2011;17(3):246-255. http://dx.doi.org/10.1111/j.1524-4741.2011.01080.x
  2. Barros AC, Sampaio Mde C. Gynecomastia: physiopatho- logy, evaluation and treatment. Sao Paulo Med J 2012; 130(3):187-197. http://dx.doi.org/10.1590/S1516-31802012000300009 Muthusamy E. Hyperthyroidism with gynaecomastia, galac- torrhoea and periodic paralysis. Singapore Med J 1991;32(5):371-372. Cheah JS. Gynaecomastia in hyperthyroidism. Singapore Med J 1971;12(4):241-243.
  3. Chan WB, Yeung VT, Chow CC, So WY, Cockram CS. Gynaecomastia as a presenting feature of thyrotoxicosis. Postgrad Med J 1999;75(882):229-231. http://dx.doi.org/10.1136/pgmj.75.882.229
  4. Kumar KV, Kumar A, Bansal R, Kalia R. Bilateral gyneco- mastia: A rare presentation of thyrotoxicosis. Indian J Endocrinol Metab 2013;17(2):357-358. http://dx.doi.org/10.4103/2230-8210.109680
  5. Tan TT, Ng ML, Wu LL, Khalid BA. Hyperthyroid graves disease--a 5 year retrospective study. Med J Malaysia 1989;44(3):224-230. Chopra IJ. Gonadal steroids and gonadotropins in hyperth- yroidism. Med Clin North Am 1975;59(5):1109-1121. http://dx.doi.org/10.1016/S0025-7125(16)31961-7
  6. Chopra IJ, Tulchinsky D. Status of estrogen-androgen balan- ce in hyperthyroid men with Graves' disease. J Clin Endocrinol Metab 1974;38(2):269-77. http://dx.doi.org/10.1210/jcem-38-2-269
  7. Southren AL, Olivo J, Gordon GG, Vittek J, Brener J, Rafii F. The conversion of androgens to estrogens in hyperthyroi- dism. J Clin Endocrinol Metab 1974;38(2):207-214. http://dx.doi.org/10.1210/jcem-38-2-207
  8. Becker KL, Winnacker JL, Matthews MJ, Higgins GA, Jr. Gynecomastia and hyperthyroidism. An endocrine and histologi- cal investigation. J Clin Endocrinol Metab 1968;28(2):277-285. http://dx.doi.org/10.1210/jcem-28-2-277